Novo Licenses to Almirall Potential First-in-Class Antibody Candidate

Almirall will have exclusive global rights to develop and commercialize the anti-IL-21 monoclonal antibody NN-8828 in several fields, including immune inflammatory dermatological indications.

Related Keywords

Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Denmark ,Spanish ,Danish ,Eli Lilly ,Karl Ziegelbauer ,Novo Nordisk ,European Union ,Resume ,Careers ,Ovo Licenses To Almirall Potential First In Class Antibody Candidate ,Iospace ,Advice ,